Preclinical Design and Clinical Translation of TB Regimens for Faster TB Treatment
Official title: Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
Funded at University of California, San Francisco · NIH-11595892 · Data updated 2026-11-12
A collaborative effort to find better TB treatment plans that could shorten therapy for people with TB by using early research findings to guide clinical steps.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | March 26, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $595,031 |
| NIH project number | 3UM1AI179699-03S1 |
| Project ID | NIH-11595892 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with tuberculosis who may be eligible for future trials or use of improved regimens once translated into clinical care.
✕Less likely to help
Early-stage preclinical work without immediate clinical testing may not benefit patients directly.
What this research studies
This project brings together experts to connect lab studies with patient care, aiming to pick promising drug combinations faster. It uses animal models and modeling to predict which regimens could work best in people, with an emphasis on translating those findings into clinical plans. The team will map out the most efficient sequence of preclinical experiments and modeling to prioritize regimens for human testing. If successful, it could help shorten treatment durations for both drug-susceptible and drug-resistant TB.
Why it matters
Potential benefit: If the work succeeds, patients could benefit from shorter, more effective TB treatment regimens.
How similar studies have gone: Previous TB research has shown that better preclinical translation can shorten regimens, though the exact path to clinical adoption remains complex.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Savic, Radojka — University of California, San Francisco
- Study coordinator: Savic, Radojka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.